TruScreen have released their preliminary unaudited financial results for the year ended 31 March 2016 to the NZAX.
- Revenue for the 12 months to 31 March 2016 exceeds NZ$1.8 millon
- TruScreen Gen II Ultra receives CE Mark and other regulatory approvals
- TruScreen Gen I gaining traction in China
- TruScreen Gen II Ultra commences commercial sales
TruScreen (NZX: TRU), the world’s only CE certified manufacturer of an electo-light tissue differentiating device for the detection of cervical cancer, today released its preliminary unaudited financial results for the year ended 31 March 2016.
Full announcement and results can be found on our Reports and Presentations page.